The global CRISPR-based gene editing market size was valued at USD 4.18 billion in 2023 and is anticipated to reach around USD 16.53 billion by 2033, growing at a CAGR of 14.74% from 2024 to 2033.
This growth is driven by the rising prevalence of genetic disorders, advancements in research and technology, supportive government initiatives, and increasing investment in biotechnology. According to the World Health Organization, over 400 million people globally suffer from genetic disorders, with conditions like cystic fibrosis, sickle cell disease, and muscular dystrophy presenting significant healthcare challenges.
CRISPR technology provides a precise and efficient method for gene editing, facilitating the development of targeted therapies that have the potential to transform the treatment landscape for various conditions. As the patient population continues to grow, there is an escalating demand for effective therapeutic solutions, positioning CRISPR as a central focus in the quest for innovative medical treatments.
Recent developments in CRISPR technology have significantly enhanced its precision and efficacy. Innovations such as CRISPR 2.0, which includes base editing and prime editing, enable researchers and clinicians to make more precise edits with fewer off-target effects, thereby expanding the range of treatable conditions. A study published by National Library of Medicines in April 2023 highlights that CRISPR technology has been successfully applied in clinical trials, with companies like Editas Medicine and CRISPR Therapeutics reporting promising results in gene therapies for conditions like Leber congenital amaurosis and beta-thalassemia. The success of these trials not only boosts confidence in CRISPR applications but also attracts increased investments from both public and private sectors, further driving the market for CRISPR-based gene editing products and services.
Government support plays a crucial role in the expansion of the market. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have begun establishing frameworks for evaluating gene editing therapies. In the U.S., the National Institutes of Health (NIH) has funded numerous CRISPR-related research projects, highlighting the importance of gene editing in addressing genetic diseases. For instance, in October 2023, the Yale School of Medicine received a substantial grant of approximately USD 40 million from the National Institutes of Health (NIH). This funding will facilitate the creation of a gene-editing platform aimed at targeting the human brain, advancing CRISPR-based gene therapy for neurological diseases. Such regulatory backing fosters a conducive environment for research and development, paving the way for commercial applications.
The U.S. CRISPR-based Gene Editing market size was exhibited at USD xx billion in 2023 and is projected to be worth around USD xx billion by 2033, poised to grow at a CAGR of xx% from 2024 to 2033.
North America dominated the CRISPR-based gene editing market with the largest revenue share of 41.88% in 2023. This leadership is largely attributed to the strong presence of major biotechnology and pharmaceutical companies, coupled with substantial investments in research and development. The region also benefits from supportive regulatory frameworks that facilitate innovation and accelerate the approval process for new therapies. Furthermore, the high prevalence of genetic disorders, which affect millions of individuals in the U.S., highlights the urgent demand for effective treatments.
U.S. CRISPR-based Gene Editing Market Trends
The CRISPR-based gene editing market in U.S. is anticipated to experience at a significant CAGR during the forecast period, due to rising investments in biotechnology and healthcare innovation. The increasing prevalence of genetic and rare diseases, which affect over 30 million people in the U.S., is propelling research efforts and funding, driving the market for products and services. In addition, the regulatory environment is becoming more conducive, with the FDA providing clearer guidelines for gene editing therapies. Recent collaborations between academic institutions and biotech firms are accelerating the development of CRISPR applications, particularly in areas such as oncology and rare genetic disorders. Furthermore, numerous government initiatives aim to bolster biotechnology research. For instance, the U.S. government has invested heavily in the "Precision Medicine Initiative," which seeks to tailor treatments to individual genetic profiles.
Europe CRISPR-based Gene Editing Market Trends
The CRISPR-based gene editing market in Europe is anticipated to grow at the fastest CAGR over the forecast period, driven by strong governmental support and a collaborative research environment. European countries are investing heavily in biotechnology research, with initiatives like Horizon Europe, which allocates substantial funding to genetic research. Regulatory agencies, such as the European Medicines Agency, are also becoming more proactive in facilitating the approval of gene editing therapies, enhancing the market's growth prospects.
The UK CRISPR-based gene editing market is expected to witness at a significant CAGR during the forecast period, fueled by the government’s strong commitment to biotechnology and research. With leading universities advancing gene editing technologies, recent initiatives like the UK Genome Innovation Fund highlight efforts to boost genetic research. This fund includes over USD 34 million investment in a cancer program led by Genomics England, aimed at using advanced genomic sequencing and AI to improve cancer diagnoses. In addition, the Medical Research Council is launching a four-year functional genomics initiative with over USD 33 million in funding, seeking to create a top-tier, industry-partnered framework. These initiatives position the UK as a key player in the CRISPR landscape, driving innovative genetic research and therapies.
The CRISPR-based gene editing market in France is anticipated to grow at the fastest CAGR over the forecast period, supported by the country’s strong focus on life sciences and biotechnology. France is home to numerous research institutions and biotech companies that are actively engaged in gene editing projects. Government initiatives, such as the French National Research Agency’s (ANR) funding for innovative health projects, further enhance the growth potential of CRISPR applications. The ANR's main funding initiative, the AAPG, supports a range of projects, including individual research, collaborative research, and team-led research. In 2022, the ANR allocated around USD 17.0 million to 29 research projects to study the COVID-19 pandemic.
Asia Pacific CRISPR-based Gene Editing Market Trends
The CRISPR-based gene editing market in Asia Pacific is anticipated to witness at the fastest CAGR of 16.96% from 2024 to 2033. This rapid expansion is primarily driven by increasing investments in biotechnology and rising awareness of gene editing technologies across the region. The prevalence of genetic disorders in countries like China and India creates significant demand for innovative therapies. Furthermore, supportive government policies and funding initiatives aimed at advancing biotechnology research are enhancing the market landscape and facilitating collaboration between academia and industry.
The China CRISPR-based gene editing market is expected to grow at a significant CAGR over the forecast period, driven by substantial government investment in life sciences and biotechnology. China’s growing healthcare needs, fueled by a rising population and increasing incidence of genetic disorders, necessitate innovative solutions. The Chinese government has implemented favorable policies to encourage research and development in gene editing, resulting in numerous clinical trials and collaborations between research institutions and biotech firms.
The CRISPR-based gene editing market in India is expected to grow at a rapid CAGR over the forecast period, driven by increasing investments in biotechnology and a rising awareness of genetic disorders. The Indian government has been actively promoting biotechnology research through initiatives like the Biotechnology Industry Research Assistance Council (BIRAC), which supports innovation in gene editing technologies. The increasing prevalence of genetic diseases in India creates significant demand for effective therapeutic solutions, positioning the country as a burgeoning hub for CRISPR applications.
Middle East and Africa CRISPR-based Gene Editing Market Trends
The CRISPR-based gene editing market in the Middle East and Africa is poised to grow at a substantial CAGR during the forecast period, driven by increasing investments in healthcare and biotechnology research. The region is increasingly recognizing the critical role of genetic research in tackling health challenges, which has led to enhanced funding and collaboration between research institutions and biotech companies. The high prevalence of genetic disorders, particularly in certain areas, coupled with a rising demand for innovative healthcare solutions, has intensified interest in CRISPR technologies. The World Health Organization reports that sickle cell disease (SCD) is the most common genetic disorder in the African region, affecting approximately 2% of the population. In sub-Saharan Africa alone, around 236,000 babies are born with SCD each year, with a staggering 90% of these infants not surviving past their fifth birthday. This urgent health crisis underscores the necessity for effective gene editing solutions in the region.
The Saudi Arabia CRISPR-based gene editing market is expected to grow at the fastest CAGR over the forecast period, supported by government initiatives aimed at diversifying the economy and investing in biotechnology. Saudi Arabia’s Vision 2030 plan emphasizes the importance of healthcare innovation, encouraging research and development in genetic therapies. The increasing prevalence of genetic diseases in the country further amplifies the demand for advanced CRISPR applications, positioning Saudi Arabia as a key player in the regional market.
| Report Attribute | Details |
| Market Size in 2024 | USD 4.80 Billion |
| Market Size by 2033 | USD 16.53 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 14.74% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product & Service, application, end use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Revvity, Inc.; Danaher Corporation; GenScript; Merck KGaA; Thermo Fisher Scientific, Inc.; Tocris Bioscience; OriGene Technologies, Inc.; Bio-Rad Laboratories; Bio-Techne; New England Biolabs, Inc. |
Product & Service Insights
The products segment of the market, which includes CRISPR kits and reagents, CRISPR libraries, and other related tools, led the market with the largest revenue share of 74.18% in 2023. The widespread adoption of CRISPR technology in research laboratories has led to a significant demand for high-quality enzymes and kits essential for gene editing applications. Furthermore, CRISPR libraries, which allow researchers to conduct high-throughput screenings and facilitate functional genomics studies, are gaining traction. These libraries are pivotal for drug discovery and the development of novel therapies, addressing critical health challenges like cancer and genetic disorders.
The services segment is expected to witness at the fastest CAGR of 15.77% over the forecast period. As CRISPR technology becomes increasingly mainstream, researchers and organizations require specialized services for effective implementation, including design, optimization, and validation of CRISPR systems. Companies such as GenScript and Integrated DNA Technologies have introduced comprehensive service packages that include gene synthesis, cell line development, and custom CRISPR libraries. These offerings simplify the research process and accelerate project timelines, making them attractive to researchers under pressure to deliver results quickly. Moreover, as educational initiatives and workshops on CRISPR technology proliferate, more researchers are seeking expert services to enhance their understanding and application of this powerful tool. This growing demand is set to propel the services segment to new heights within the market.
Application Insights
Based on application, the biomedical segment led the market with the largest revenue share of 81.93% in 2023 and is also projected to witness at the fastest CAGR of 15.09% during the forecast period. This growth is fueled by several key drivers, including the increasing prevalence of genetic disorders and cancers, alongside significant advancements in CRISPR technology. CRISPR technology's ability to precisely edit genes offers transformative potential for conditions such as sickle cell disease and Duchenne muscular dystrophy, driving research and investment in this area. In oncology, CRISPR's application in developing targeted therapies has garnered attention, with clinical trials underway for various cancer showcasing promising results in altering tumor genetics.
The rising emphasis on personalized medicine is driving demand for advanced diagnostics, where CRISPR can enhance disease detection and monitoring. In addition, the field of ophthalmology is experiencing breakthroughs, with trials exploring CRISPR applications to treat conditions such as Leber congenital amaurosis, further expanding the scope of this segment.
End Use Insights
Based on end use, the pharmaceutical & biotechnology companies segment led the market with the largest revenue market share of 46.51% in 2023. Pharmaceutical and biotechnology companies are at the forefront of addressing a range of genetic disorders and complex diseases, such as sickle cell anemia, cystic fibrosis, and various cancers, by leveraging CRISPR technology to develop targeted therapies. Recent industry developments further underscore the growth potential of this segment. Numerous biotech firms are actively conducting clinical trials that employ CRISPR technology, with regulatory agencies increasingly supportive of these initiatives. This trend reflects a growing confidence in the safety and efficacy of CRISPR applications. For instance, in May 2023, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced a new non-exclusive licensing agreement. This collaboration focuses on utilizing CRISPR Therapeutics’ CRISPR/Cas9 gene editing technology to expedite the development of Vertex’s hypoimmune cell therapies for type 1 diabetes, showcasing the practical applications and transformative potential of CRISPR in treating chronic conditions.
The contract research organizations segment is projected to witness at the fastest CAGR of 17.13% over the forecast period. This growth is driven by the increasing complexity of research and development in biotechnology, alongside a rising demand for specialized expertise in gene editing. CROs play a crucial role by providing essential services such as assay development, regulatory compliance, and clinical trial management. This enables pharmaceutical and biotech companies to concentrate on their core competencies while ensuring timely and budget-conscious project completion.
The following are the leading companies in the CRISPR-based gene editing market. These companies collectively hold the largest market share and dictate industry trends.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the CRISPR-based Gene Editing market.
By Product & Service
By Application
By End Use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product & Service Segment
1.2.2. Application Segment
1.2.3. End-use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. CRISPR-based Gene Editing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of genetic disorders
3.2.1.2. Growing investments in biotechnology and healthcare research
3.2.1.3. Advancements in CRISPR technology and applications
3.2.2. Market restraint analysis
3.2.2.1. Ethical concerns surrounding gene editing
3.2.2.2. High costs associated with CRISPR research and development
3.3. CRISPR-based Gene Editing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. CRISPR-based Gene Editing Market: Product & Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global CRISPR-based Gene Editing Market Product & Service Movement Analysis
4.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Product & Service, 2021 to 2033(USD Million)
4.4. Products
4.4.1. Products market estimates and forecasts, 2021 to 2033(USD Million)
4.4.2. CRISPR Kits & Reagents
4.4.2.1. CRISPR kits & reagents market estimates and forecasts, 2021 to 2033(USD Million)
4.4.3. CRISPR Libraries
4.4.3.1. CRISPR libraries market estimates and forecasts, 2021 to 2033(USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2021 to 2033(USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2021 to 2033(USD Million)
Chapter 5. CRISPR-based Gene Editing Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global CRISPR-based Gene Editing Market Application Movement Analysis
5.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Application, 2021 to 2033(USD Million)
5.4. Biomedical
5.4.1. Biomedical market estimates and forecasts, 2021 to 2033(USD Million)
5.4.2. Therapeutic Development
5.4.2.1. Therapeutic development market estimates and forecasts, 2021 to 2033(USD Million)
5.4.2.2. By Indication
5.4.2.2.1. Genetic Disorders
5.4.2.2.1.1. Genetic Disorders market estimates and forecasts, 2021 to 2033(USD Million)
5.4.2.2.2. Oncology
5.4.2.2.2.1. Oncology market estimates and forecasts, 2021 to 2033(USD Million)
5.4.2.2.3. Ophthalmology
5.4.2.2.3.1. Ophthalmology market estimates and forecasts, 2021 to 2033(USD Million)
5.4.2.2.4. Others
5.4.2.2.4.1. Others market estimates and forecasts, 2021 to 2033(USD Million)
5.4.2.3. By Delivery Method
5.4.2.3.1. Ex Vivo
5.4.2.3.2. Ex vivo market estimates and forecasts, 2021 to 2033(USD Million
5.4.2.3.3. In Vivo
5.4.2.3.4. In vivo market estimates and forecasts, 2021 to 2033(USD Million
5.4.3. Disease Diagnostics
5.4.3.1. Disease diagnostics market estimates and forecasts, 2021 to 2033(USD Million)
5.5. Agricultural applications
5.5.1. Agricultural applications market estimates and forecasts, 2021 to 2033(USD Million)
5.5.2. Plant Engineering
5.5.2.1. Plant engineering market estimates and forecasts, 2021 to 2033(USD Million)
5.5.3. Farm Animals Engineering
5.5.3.1. Farm animals engineering market estimates and forecasts, 2021 to 2033(USD Million)
5.5.4. Others
5.5.4.1. Others market estimates and forecasts, 2021 to 2033(USD Million)
Chapter 6. CRISPR-based Gene Editing Market: End-use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global CRISPR-based Gene Editing Market End-use Movement Analysis
6.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by End-use, 2021 to 2033(USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 to 2033(USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & research institutes market estimates and forecasts, 2021 to 2033(USD Million)
6.6. Contract Research Organizations
6.6.1. Contract research organizations market estimates and forecasts, 2021 to 2033(USD Million)
Chapter 7. CRISPR-based Gene Editing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America market estimates and forecasts, 2021 to 2033(USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Target disease prevalence
7.4.2.4. Regulatory framework
7.4.2.5. U.S. market estimates and forecasts, 2021 to 2033(USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Target disease prevalence
7.4.3.4. Regulatory framework
7.4.3.5. Canada market estimates and forecasts, 2021 to 2033(USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Target disease prevalence
7.4.4.4. Regulatory framework
7.4.4.5. Mexico market estimates and forecasts, 2021 to 2033(USD Million)
7.5. Europe
7.5.1. Europe market estimates and forecasts, 2021 to 2033(USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Target disease prevalence
7.5.2.4. Regulatory framework
7.5.2.5. UK market estimates and forecasts, 2021 to 2033(USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Target disease prevalence
7.5.3.4. Regulatory framework
7.5.3.5. Germany market estimates and forecasts, 2021 to 2033(USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Target disease prevalence
7.5.4.4. Regulatory framework
7.5.4.5. France market estimates and forecasts, 2021 to 2033(USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Target disease prevalence
7.5.5.4. Regulatory framework
7.5.5.5. Italy market estimates and forecasts, 2021 to 2033(USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Target disease prevalence
7.5.6.4. Regulatory framework
7.5.6.5. Spain market estimates and forecasts, 2021 to 2033(USD Million)
7.5.7. Denmark
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Target disease prevalence
7.5.7.4. Regulatory framework
7.5.7.5. Denmark market estimates and forecasts, 2021 to 2033(USD Million)
7.5.8. Sweden
7.5.8.1. Key country dynamics
7.5.8.2. Competitive scenario
7.5.8.3. Target disease prevalence
7.5.8.4. Regulatory framework
7.5.8.5. Sweden market estimates and forecasts, 2021 to 2033(USD Million)
7.5.9. Norway
7.5.9.1. Key country dynamics
7.5.9.2. Competitive scenario
7.5.9.3. Target disease prevalence
7.5.9.4. Regulatory framework
7.5.9.5. Norway market estimates and forecasts, 2021 to 2033(USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific market estimates and forecasts, 2021 to 2033(USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Target disease prevalence
7.6.2.4. Regulatory framework
7.6.2.5. Japan market estimates and forecasts, 2021 to 2033(USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Target disease prevalence
7.6.3.4. Regulatory framework
7.6.3.5. China market estimates and forecasts, 2021 to 2033(USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Competitive scenario
7.6.4.3. Target disease prevalence
7.6.4.4. Regulatory framework
7.6.4.5. India market estimates and forecasts, 2021 to 2033(USD Million)
7.6.5. Australia
7.6.5.1. Key country dynamics
7.6.5.2. Competitive scenario
7.6.5.3. Target disease prevalence
7.6.5.4. Regulatory framework
7.6.5.5. Australia market estimates and forecasts, 2021 to 2033(USD Million)
7.6.6. South Korea
7.6.6.1. Key country dynamics
7.6.6.2. Competitive scenario
7.6.6.3. Target disease prevalence
7.6.6.4. Regulatory framework
7.6.6.5. South Korea market estimates and forecasts, 2021 to 2033(USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Competitive scenario
7.6.7.3. Target disease prevalence
7.6.7.4. Regulatory framework
7.6.7.5. Thailand market estimates and forecasts, 2021 to 2033(USD Million)
7.7. Latin America
7.7.1. Latin America market estimates and forecasts, 2021 to 2033(USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Target disease prevalence
7.7.2.4. Regulatory framework
7.7.2.5. Brazil market estimates and forecasts, 2021 to 2033(USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Target disease prevalence
7.7.3.4. Regulatory framework
7.7.3.5. Argentina market estimates and forecasts, 2021 to 2033(USD Million)
7.8. MEA
7.8.1. MEA market estimates and forecasts, 2021 to 2033(USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Competitive scenario
7.8.2.3. Target disease prevalence
7.8.2.4. Regulatory framework
7.8.2.5. South Africa market estimates and forecasts, 2021 to 2033(USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Competitive scenario
7.8.3.3. Target disease prevalence
7.8.3.4. Regulatory framework
7.8.3.5. Saudi Arabia market estimates and forecasts, 2021 to 2033(USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Competitive scenario
7.8.4.3. Target disease prevalence
7.8.4.4. Regulatory framework
7.8.4.5. UAE market estimates and forecasts, 2021 to 2033(USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Competitive scenario
7.8.5.3. Target disease prevalence
7.8.5.4. Regulatory framework
7.8.5.5. Kuwait market estimates and forecasts, 2021 to 2033(USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2023
8.4. List of Key Buyers for CRISPR-based Gene Editing Products & Services
8.5. Company Profiles/Listing
8.5.1. Revvity, Inc.
8.5.1.1. Company overview
8.5.1.2. Financial performance
8.5.1.3. Product/Service benchmarking
8.5.1.4. Strategic initiatives
8.5.2. Danaher Corporation
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product/Service benchmarking
8.5.2.4. Strategic initiatives
8.5.3. GenScript
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product/Service benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Merck KGaA
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product/Service benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Thermo Fisher Scientific, Inc.
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product/Service benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Tocris Bioscience
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product/Service benchmarking
8.5.6.4. Strategic initiatives
8.5.7. OriGene Technologies, Inc.
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product/Service benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bio-Rad Laboratories
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product/Service benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Bio-Techne
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product/Service benchmarking
8.5.9.4. Strategic initiatives
8.5.10. New England Biolabs, Inc.
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product/Service benchmarking
8.5.10.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers